Meeting
2024 ASCO Annual Meeting
IOV-3001, a modified interleukin-2 fusion protein, for potential use in tumor-infiltrating lymphocyte cell therapy regimens.
Authors
Michelle R. Abelson
Iovance Biotherapeutics, Inc., San Carlos, CA
Michelle R. Abelson , Sadie Johnson , Joanna Poprawski , Jamie L. Blauvelt , Sean Hall , Hequn Yin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2552)
DOI
10.1200/JCO.2024.42.16_suppl.2552
Abstract #
2552
Poster Bd #
31
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Antitumor activity of T cells expressing a novel anti-folate receptor alpha (FOLR1) costimulatory antigen receptor (CoStAR) in a human xenograft murine solid tumor model and implications for in-human studies.
First Author: Owen R. Moon
Poster
2022 ASCO Annual Meeting
A phase 1 adoptive cell therapy using drug-enhanced, tumor-infiltrating lymphocytes, DeTIL-0255, in adults with advanced malignancies.
First Author: Eugenia Girda
Poster
2022 ASCO Annual Meeting
A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.
First Author: Christine H. Chung
Poster
2024 ASCO Annual Meeting
Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients.
First Author: Rongsu Qi